Dr. Willmar Schwabe
Dr. Willmar Schwabe is a fifth-generation, family-owned German pharmaceutical company that develops, manufactures, and distributes evidence-based phytopharmaceutical (plant-based) medicines through brands like Tebonin, Umckaloabo, and Lasea, selling primarily via pharmacies to consumers and healthcare professionals across Germany and internationally.
- Company typePrivate
- Founded1866
- HeadquartersKarlsruhe, Germany
- Headcount1,001–5,000
- GTM typeB2C
- OfferingHardware or Manufacturing
What Dr. Willmar Schwabe does
Dr. Willmar Schwabe GmbH & Co. KG is a German pharmaceutical manufacturer specializing in evidence-based phytopharmaceuticals (plant-based medicines), headquartered in Karlsruhe and founded in Leipzig in 1866 by apothecary Dr. Willmar Schwabe. The company develops, produces, and distributes standardized herbal medicines through a portfolio of brands including Tebonin (Ginkgo biloba EGb 761 for cognitive function, dizziness, tinnitus), Umckaloabo (Pelargonium sidoides EPs 7630 for respiratory infections), Lasea (Silexan lavender oil for anxiety and sleep disorders), Crataegutt (hawthorn for cardiovascular health), Prostagutt (urological), Neuroplant, Vitango, Hametum, and others, addressing conditions ranging from cognitive decline and anxiety to bronchitis and wound healing.
The company's core technology centers on proprietary, standardized botanical extracts developed over more than 160 years, with multi-target mechanisms of action validated through controlled clinical trials under the same regulatory standards applied to synthetic pharmaceuticals. It operates a fully vertically integrated production model spanning its own ecologically certified cultivation operations (Terra Medica), specialized extraction facilities, and in-house active ingredient manufacturing (via subsidiary Schwabe Extracta), supported by more than 100 R&D staff. Dr. Willmar Schwabe has accumulated over 800 drug approvals worldwide for its phytopharmaceutical products.
Commercially, the company generates revenue through one-time sales of OTC and prescription herbal medicines distributed primarily via pharmacies in Germany and internationally through Schwabe Group subsidiaries, with selected products eligible for voluntary reimbursement by German statutory health insurers (AOK, DAK, TK). The business is 100% family-owned in its fifth generation under CEO Olaf Schwabe, self-financed, and structured within the broader Schwabe Group alongside subsidiaries Deutsche Homöopathie-Union (DHU, homeopathic medicines) and OTX Force GmbH (distribution). Group revenue is approximately €950 million, with 4,000+ employees worldwide (1,400 in Germany).
Dr. Willmar Schwabe firmographics
Firmographics- Name
- Dr. Willmar Schwabe
- Legal name
- Dr. Willmar Schwabe GmbH & Co. KG
- Website
- https://www.schwabe.de
- Company type
- Private
- Founded year
- 1866
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Dr. Willmar Schwabe is a fifth-generation, family-owned German pharmaceutical company that develops, manufactures, and distributes evidence-based phytopharmaceutical (plant-based) medicines through brands like Tebonin, Umckaloabo, and Lasea, selling primarily via pharmacies to consumers and healthcare professionals across Germany and internationally.
- Ownership category
- akta.pro rank
Dr. Willmar Schwabe industry classification
Industry- Product category
- Phytopharmaceuticals / Herbal Medicines
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD)
- akta.pro secondary industries
- Herbal & Botanical Supplements (CRADAGAD), Healthy Aging & Cognitive Support Supplements (CRADAGAM), Sleep, Stress & Mood Support (HLAIADAG)
Keywords
Where Dr. Willmar Schwabe is headquartered
LocationHeadquarters
- HQ city
- Karlsruhe
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Dr. Willmar Schwabe business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Phytopharmaceutical Product Sales: Sale of over-the-counter (OTC) and prescription herbal medicines through pharmacies in Germany and internationally. Products include Tebonin, Umckaloabo, Lasea, Crataegutt, Prostagutt, and others targeting conditions including cognitive decline, respiratory infections, anxiety, cardiovascular health, and urological conditions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Pharmacy-distributed herbal medicines available with or without prescription |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Dr. Willmar Schwabe product offering
Product offeringCore offering
Dr. Willmar Schwabe develops, manufactures, and distributes standardized phytopharmaceutical (plant-based) medicines for conditions including cognitive decline, dizziness, tinnitus, respiratory infections, anxiety, sleep disorders, cardiovascular health, urological complaints, skin conditions, and digestion. Products are built on proprietary special extracts (EGb 761 Ginkgo biloba, Silexan lavender oil, EPs 7630 Pelargonium sidoides) and sold primarily through German pharmacies as OTC and prescription medicines, with over 800 drug approvals worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- Tebonin: Ginkgo biloba special extract EGb 761 product line for cognitive function, dizziness, and tinnitus
- Crataegutt
- Umckaloabo
- Lasea
- Prostagutt
- Neuroplant
- Pinimenthol
- Carmenthin
- Refluthin
- Hametum
- Venoplant
- Vitango
- Euvegal
- Doloplant
- Dermaplant
- Terra Medica
Products and services
- Tebonin® Ginkgo biloba special extract EGb 761 product line for cognitive function, dizziness, tinnitus, and age-related memory loss; sold through German pharmacies as OTC and prescription medicine.
- Umckaloabo® Pelargonium sidoides extract (EPs 7630) product line for acute bronchitis and respiratory infections; sold through pharmacies.
- Lasea® Silexan medicinal lavender oil product line for inner restlessness, anxiety-related symptoms, and resulting sleep disorders; sold through pharmacies.
- Crataegutt® Hawthorn extract product line for heart and circulation support; sold through pharmacies.
- Prostagutt® Saw palmetto and nettle root combination for urinary symptoms related to benign prostatic enlargement; sold through pharmacies.
- Hametum® Hämorrhoiden Hamamelis (witch hazel) product line for hemorrhoid treatment; sold through pharmacies. Hametum has been marketed since the 1920s.
- Hametum® Haut (Wund- und Heilsalbe; Medizinische Hautpflege) Hamamelis-based wound healing ointment and medicinal skincare line for skin conditions and wound healing; sold through pharmacies.
- Refluthin® Fig cactus extract combined with mineral acid buffers for quick heartburn relief; sold through pharmacies.
- Neuroplant® St. John's wort product line for depressive moods; sold through pharmacies.
- Pinimenthol® Eucalyptus and pine needle oil product line for colds and respiratory relief; sold through pharmacies.
- Carmenthin® Peppermint oil and caraway oil combination for digestive disorders and flatulence; sold through pharmacies.
- Euvegal® Valerian and hop product line for sleep disorders; sold through pharmacies.
- Doloplant® Devil's claw product line for muscle and joint pain; sold through pharmacies.
- Dermaplant® Phytopharmaceutical product for skin conditions including atopic dermatitis; sold through pharmacies.
- Venoplant® Horse chestnut seed extract for venous insufficiency; sold through pharmacies.
- Vitango® Rhodiola rosea product line for stress and fatigue; sold through pharmacies.
- Tebonin® Schwindel-App Mobile patient-support application offering physiotherapy exercise guidance for dizziness, including Epley maneuver for benign paroxysmal positional vertigo (BPPV) and vestibular rehabilitation exercises; available on iOS and Android.
Companies that use Dr. Willmar Schwabe
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Dr. Willmar Schwabe technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Dr. Willmar Schwabe partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Deutsche Homöopathie-Union (DHU)coreThe Deutsche Homöopathie-Union is one of the leading manufacturers of homeopathic medicines. DHU operates as a separate business unit within the Schwabe Group, handling development, manufacturing, and distribution of homeopathic products while Dr. Willmar Schwabe focuses on phytopharmaceuticals.
- Schwabe ExtractacoreSchwabe Extracta is a highly specialized active ingredient manufacturer that produces the active ingredients for the entire Schwabe Group.
- OTX Force GmbHminorOTX Force GmbH is an independent sales company of Dr. Willmar Schwabe operating as a separate distribution entity.
- Pharma DeutschlandminorDr. Willmar Schwabe is a member of Pharma Deutschland, the leading industry association for pharmaceutical companies in Germany.
- Pro Grünes RezeptminorDr. Willmar Schwabe supports the 'Pro Grünes Rezept' initiative, which promotes awareness of green prescriptions for non-prescription herbal medicines and their potential reimbursement by health insurers.
- Smallholder Farms (Global)minorDr. Willmar Schwabe works directly with small agricultural businesses globally (e.g., valerian in Kyrgyzstan, lavender in Southern Europe) that prioritize environmentally friendly cultivation, ensuring sustainable raw material sourcing.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Dr. Willmar Schwabe competitors and assessment
Company assessmentDirect peers
- Bionorica SE: Bionorica is one of the world's leading manufacturers of phytopharmaceuticals, producing evidence-based herbal medicines for respiratory, gynecological, and urological conditions. It is the most direct comparable to Schwabe given the overlapping focus on standardized plant-based drug products sold through pharmacy channels.
- Heel GmbH: Heel is a German pharmaceutical company specializing in natural, plant-based and homeopathic medicines, also based in Baden-Württemberg. The combination of phytopharmaceutical and homeopathic product focus is closely aligned with Schwabe's portfolio strategy (note DHU is Schwabe's homeopathy subsidiary).
- Salus-Haus GmbH & Co. KG: Salus-Haus is a German manufacturer of herbal medicinal products and natural health products, also family-owned. Overlap with Schwabe is strong in tonics, plant-based juices, and pharmacy-distributed herbal remedies.
- Klosterfrau Melisana GmbH: Klosterfrau is a traditional German manufacturer of plant-based medicines (e.g., Klosterfrau Melissengeist) and OTC health products. Comparable as a pharmacy-channel herbal medicine specialist with a similar heritage positioning to Schwabe.
- Steigerwald Arzneimittelwerk GmbH: Steigerwald is a German manufacturer of phytopharmaceuticals, particularly known for Iberogast. It is part of Bayer's consumer health division but operates as a focused herbal medicine manufacturer comparable to Schwabe's specialty positioning.
Others
- Schwabe Group subsidiary: Deutsche Homöopathie-Union (DHU): DHU is a Schwabe Group subsidiary handling homeopathic medicines. While a related entity rather than a competitor, it represents the homeopathic medicine category that overlaps thematically with phytopharmaceuticals and is part of the same corporate family for context.
Broad incumbents
- Bayer Consumer Health (Iberogast, Aspirin Natural): Bayer's Consumer Health division offers herbal OTC products (including Steigerwald's Iberogast) alongside mainstream consumer health brands. Bayer is a much larger, publicly-listed company with broader portfolio reach, but its phytopharmaceutical segment competes directly with Schwabe.
- Sanofi Consumer Healthcare: Sanofi operates a large consumer healthcare division with herbal and natural product lines in European markets. Comparable as a broad incumbent with plant-based OTC offerings, though the focus is wider than phytopharmaceuticals alone.
Emerging players
- FLORA (Ceres Heilmittel AG): Ceres is a Swiss specialist in plant-based tinctures and phytotherapeutic medicines, focused on a smaller niche of high-quality plant-based remedies. Comparable as an emerging specialist in the same herbal medicine category as Schwabe, but with a smaller, more focused portfolio.
Regional players
- Phytomed AG: Zeller AG (Phytomed) is a Swiss manufacturer of standardized phytopharmaceuticals, particularly for gynecological indications. Comparable in technology and regulatory approach (standardized extracts, drug approvals) but primarily serves the Swiss market, making it a regional peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Dr. Willmar Schwabe social profiles
Digital presenceDr. Willmar Schwabe financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dr. Willmar Schwabe leadership team
Management profileNumber of profiles
Profiles8 records
Dr. Willmar Schwabe subsidiaries and ownership
Company hierarchySubsidiaries3 records
Dr. Willmar Schwabe funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dr. Willmar Schwabe M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dr. Willmar Schwabe
What does Dr. Willmar Schwabe do?
Dr. Willmar Schwabe develops, manufactures, and distributes standardized phytopharmaceutical (plant-based) medicines for conditions including cognitive decline, dizziness, tinnitus, respiratory infections, anxiety, sleep disorders, cardiovascular health, urological complaints, skin conditions, and digestion. Products are built on proprietary special extracts (EGb 761 Ginkgo biloba, Silexan lavender oil, EPs 7630 Pelargonium sidoides) and sold primarily through German pharmacies as OTC and prescription medicines, with over 800 drug approvals worldwide.
Is Dr. Willmar Schwabe a public or private company?
Dr. Willmar Schwabe is a private company. It is classified as family owned and is currently operating.
When was Dr. Willmar Schwabe founded?
Dr. Willmar Schwabe was founded in 1866. It employs 1,001 to 5,000 people.
Where is Dr. Willmar Schwabe based?
Dr. Willmar Schwabe is headquartered in Karlsruhe, Germany, in the Europe region.
How does Dr. Willmar Schwabe make money?
One revenue line is on record: phytopharmaceutical Product Sales.
Who are Dr. Willmar Schwabe's main competitors?
Direct peers on record are Bionorica SE, Heel GmbH, Salus-Haus GmbH & Co. KG, Klosterfrau Melisana GmbH and Steigerwald Arzneimittelwerk GmbH. Schwabe Group subsidiary: Deutsche Homöopathie-Union (DHU) is listed as an others. Broad incumbents are Bayer Consumer Health (Iberogast, Aspirin Natural) and Sanofi Consumer Healthcare. FLORA (Ceres Heilmittel AG) is listed as an emerging player. Phytomed AG is listed as a regional player.
Does Dr. Willmar Schwabe have an API?
No public API is recorded for Dr. Willmar Schwabe.
What industry is Dr. Willmar Schwabe in?
Dr. Willmar Schwabe's product category is Phytopharmaceuticals / Herbal Medicines. Its primary akta.pro industry code is AFAJAKAD, Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts), with a secondary code of CRADAGAD, Herbal & Botanical Supplements. Its NAICS code is 325411 and its SIC code is 2833.